BioCryst Pharmaceuticals, Inc. (BCRX)Healthcare | Drug Manufacturers - Specialty & Generic | Durham, United States | NasdaqGS
9.91 USD
-0.54
(-5.167%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:25 a.m. EDT
The immediate catalyst is a classic turnaround story where the market is pricing in a shift from internal discovery to a more durable rare-disease innovation model. Fundamentally, the company shows a massive disconnect between its deteriorating operational metrics—specifically negative operating margins and a trailing EPS of -$1.77—and its robust cash generation, which produced nearly $265 million in free cash flow. This liquidity cushion allows management to execute cost-cutting measures, such as closing the Birmingham R&D hub, without threatening solvency. The valuation is compelling at roughly 3x sales with a forward P/E of 11, suggesting the market has already factored in the worst-case scenarios regarding profitability. However, the lack of a dividend and the persistent losses mean this is not a defensive hold; it is a high-risk, high-reward speculative play dependent on the success of the HAE franchise and the execution of the new business model. The recent price surge confirms growing institutional interest in this pivot. |
| Model | MAE |
|---|---|
| MSTL_90 ✓ | 0.055893 |
| MSTL_90_115 | 0.059545 |
| MSTL_115 | 0.066842 |
| MSTL | 0.073385 |
| AutoTheta | 0.076703 |
| AutoARIMA | 0.079475 |
| AutoETS | 0.079507 |
Forecast horizon: 60 days | Selected: MSTL_90
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 2.44 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.289 |
| Excess Kurtosis | 0.00 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 4.059 |
| Market Cap | 2,518,752,000 |
| Forward P/E | 10.71 |
| Beta | 0.54 |
| Profit Margins | -51.71% |
| Website | https://www.biocryst.com |
As of July 11, 2026, 4:25 a.m. EDT: Speculators are positioning for a moderate upside move, evidenced by heavy open interest in out-of-the-money calls (12.0 and 15.0 strikes) relative to puts. While ATM call volume is significant, the skew toward OTM calls suggests a bullish bias rather than a hedging strategy. Put activity is concentrated at lower strikes (7.0-9.0), indicating a floor but lacking the aggressive volume seen in the call side.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.13646793 |
| Address1 | 4,505 Emperor Boulevard |
| Address2 | Suite 200 |
| All Time High | 37.25 |
| All Time Low | 0.6 |
| Ask | 11.33 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 5,655,830 |
| Average Daily Volume3 Month | 5,052,508 |
| Average Volume | 5,052,508 |
| Average Volume10Days | 5,655,830 |
| Beta | 0.543 |
| Bid | 8.6 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | -2.18 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.91 |
| Current Ratio | 1.912 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 10.23 |
| Day Low | 9.8 |
| Display Name | BioCryst Pharmaceuticals |
| Earnings Call Timestamp End | 1,778,070,600 |
| Earnings Call Timestamp Start | 1,778,070,600 |
| Earnings Timestamp | 1,778,070,600 |
| Earnings Timestamp End | 1,785,760,200 |
| Earnings Timestamp Start | 1,785,760,200 |
| Ebitda | 326,456,992 |
| Ebitda Margins | 0.36858 |
| Enterprise To Ebitda | 9.614 |
| Enterprise To Revenue | 3.543 |
| Enterprise Value | 3,138,435,072 |
| Eps Current Year | 0.61 |
| Eps Forward | 0.925 |
| Eps Trailing Twelve Months | -1.77 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 919 859 1314 |
| Fifty Day Average | 9.1606 |
| Fifty Day Average Change | 0.74940014 |
| Fifty Day Average Change Percent | 0.08180688 |
| Fifty Two Week Change Percent | 13.646793 |
| Fifty Two Week High | 11.22 |
| Fifty Two Week High Change | -1.3100004 |
| Fifty Two Week High Change Percent | -0.11675583 |
| Fifty Two Week Low | 6.0 |
| Fifty Two Week Low Change | 3.9099998 |
| Fifty Two Week Low Change Percent | 0.65166664 |
| Fifty Two Week Range | 6.0 - 11.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 762,791,400,000 |
| Float Shares | 221,042,724 |
| Forward Eps | 0.925 |
| Forward P E | 10.713513 |
| Free Cashflow | 264,383,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 435 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.76627 |
| Gross Profits | 678,697,024 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01202 |
| Held Percent Institutions | 1.01382 |
| Implied Shares Outstanding | 254,162,660 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ir Website | http://investor.shareholder.com/biocryst/index.cfm |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina. |
| Long Name | BioCryst Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 2,518,752,000 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_25594 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -457,983,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,518,751,960 |
| Number Of Analyst Opinions | 11 |
| Open | 10.13 |
| Operating Cashflow | 313,095,008 |
| Operating Margins | -0.024530001 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 9.39 |
| Phone | 919 859 1302 |
| Pre Market Change | 0.22000027 |
| Pre Market Change Percent | 2.2199826 |
| Pre Market Price | 10.13 |
| Pre Market Time | 1,784,035,500 |
| Previous Close | 10.45 |
| Price Eps Current Year | 16.245901 |
| Price Hint | 2 |
| Price To Book | -4.5458713 |
| Price To Sales Trailing12 Months | 2.843747 |
| Profit Margins | -0.51708 |
| Quick Ratio | 1.779 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.45455 |
| Region | US |
| Regular Market Change | -0.54 |
| Regular Market Change Percent | -5.16746 |
| Regular Market Day High | 10.23 |
| Regular Market Day Low | 9.8 |
| Regular Market Day Range | 9.8 - 10.23 |
| Regular Market Open | 10.13 |
| Regular Market Previous Close | 10.45 |
| Regular Market Price | 9.91 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 3,097,485 |
| Return On Assets | 0.4262 |
| Revenue Growth | 0.075 |
| Revenue Per Share | 4.059 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 254,162,660 |
| Shares Percent Shares Out | 0.1916 |
| Shares Short | 48,685,241 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 36,651,044 |
| Short Name | BioCryst Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.19299999 |
| Short Ratio | 8.38 |
| Source Interval | 15 |
| State | NC |
| Symbol | BCRX |
| Target High Price | 32.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 21.0 |
| Target Median Price | 17.0 |
| Total Cash | 238,400,000 |
| Total Cash Per Share | 0.938 |
| Total Debt | 858,083,008 |
| Total Revenue | 885,715,968 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.77 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.09035 |
| Two Hundred Day Average Change | 1.8196497 |
| Two Hundred Day Average Change Percent | 0.22491606 |
| Type Disp | Equity |
| Volume | 3,097,485 |
| Website | https://www.biocryst.com |
| Zip | 27,703 |